🔎 Trials Near Me

Home › COPD › North Carolina

COPD clinical trials in North Carolina

22 studies for COPD are looking for participants at sites in North Carolina.

Cities in North Carolina

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

  • American Health Research - Charlotte- Site Number : 8400013, Charlotte
  • Atrium Health Wake Forest Baptist Pulmonary, Sleep And Allergy- Site Number : 8400004, Winston-Salem
RecruitingPhase 4
Ages 40 to 85 · All sexes · Updated Sep 22, 2026 · NCT07053423

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  • Duke Asthma, Allergy and Airway Center- Site Number : 8400047, Durham
  • Advanced Respiratory and Sleep Medicine - Hickory- Site Number : 8400013, Hickory
  • Science 37, Llc- Site Number : 8400154, Morrisville
  • and 1 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 22, 2026 · NCT07190209

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

  • WB Contracted Clinical Research Site, Charlotte
RecruitingPhase 2
Ages 40 to 80 · All sexes · Updated Sep 15, 2026 · NCT07646587

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

  • East Carolina University- Site Number : 8400102, Greenville
  • Piedmont Healthcare - Family Medicine- Site Number : 8400022, Statesville
  • All-Trials Clinical Research- Site Number : 8400008, Winston-Salem
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 15, 2026 · NCT07190222

Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD

  • Southeastern Research Center, Winston-Salem
RecruitingPhase 4
Ages 60 and older · All sexes · Updated Sep 14, 2026 · NCT07816835

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  • Research Site, New Bern
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 9, 2026 · NCT07082738

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  • Research Site, Charlotte
  • Research Site, Concord
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  • Research Site, High Point
  • Research Site, Kings Mountain
  • Research Site, New Bern
  • and 1 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06883305

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

  • University of North Carolina Clinical Research Center, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06603246

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

  • Duke, Durham
RecruitingObservational study
Ages 40 and older · All sexes · Updated Sep 1, 2026 · NCT07612878

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  • Salem Chest Specialists, Winston-Salem
  • Southeastern Research Center, Winston-Salem
RecruitingPhase 2/3
Ages 35 to 80 · All sexes · Updated Aug 31, 2026 · NCT07363694

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

  • Duke Asthma Allergy and Airway Center, Durham
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Aug 27, 2026 · NCT07037836

Photon-counting CT in Chest Imaging

  • Duke University Hospital, Durham
Recruiting
All ages · All sexes · Updated Aug 26, 2026 · NCT07031336

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  • Research Site, Greensboro
  • Research Site, Greenville
  • Research Site, Huntersville
  • and 3 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Aug 26, 2026 · NCT06283966

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

  • Carolina Research Center, Inc., Shelby
RecruitingPhase 2
Ages 40 to 85 · All sexes · Updated Aug 7, 2026 · NCT07684820

STRIVE Post-Market Registry Study

  • Duke University Medical Center, Durham
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT04302272

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  • GSK Investigational Site, Winston-Salem
RecruitingPhase 3
Ages 40 to 75 · All sexes · Updated Jul 28, 2026 · NCT07177339

SPIROMICS Study of Early COPD Progression (SOURCE)

  • Wake Forest, Winston-Salem
RecruitingObservational studyHealthy volunteers welcome
Ages 30 to 55 · All sexes · Updated Jun 3, 2026 · NCT05033990

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

  • Wake Forest School of Medicine, Salem
Recruiting
Ages 40 to 80 · All sexes · Updated Apr 28, 2026 · NCT07051707

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  • GSK Investigational Site, Shelby
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Apr 9, 2026 · NCT06961214

Pulmonary Hypertension SOLAR

  • Duke University Medical Center, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 24, 2026 · NCT04778046

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

  • Wakemed, Raleigh
RecruitingObservational study
Ages 50 and older · All sexes · Updated Aug 5, 2025 · NCT06122077

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.